Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9505466 | 0.85 | CYP19A1 (0.43) | FABP7FABP5KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9503261 | 0.84 | CYP19A1 (0.42) | FABP7FABP5KDM4EMEN1KMT2A | |
| SCHEMBL9702126 | 0.75 | SMN1; SMN2 (0.57) | KDM4EMEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL1397381 | 0.74 | SLC6A3 (0.45) | KDM4EPDE4ALMNATSHRCYP3A4 | |
| SCHEMBL9503402 | 0.74 | SMN1; SMN2 (0.41) | KDM4EMEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL9505434 | 0.73 | MEN1 (0.42) | KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9507117 | 0.73 | MEN1 (0.42) | KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9503372 | 0.73 | SMN1; SMN2 (0.41) | KDM4EMEN1GAAKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9504445 | 0.72 | MEN1 (0.42) | KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9505502 | 0.72 | MEN1 (0.42) | KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144613-A1 | Combined use of DPP-IV Inhibitors and Gastrin Compounds | WARATAH PHARMACEUTICALS, INC. (CA) | 2010-06-10 | — | — | US | disclosed |
| US-7524837-B2 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-20090054314-A1 | Combined use of DPP-IV inhibitors and gastrin compounds | WARATAH PHARMACEUTICALS INC. (CA) | 2009-02-26 | — | — | US | disclosed |
| EP-1971363-A1 | COMBINATION TREATMENTS WITH GASTRIN AGONISTS FOR DIABETES AND RELATED DISEASES | Waratah Pharmaceuticals, Inc. (CA) | 2008-09-24 | — | — | EP | disclosed |
| EP-1951286-A1 | COMBINED USE OF DPP IV INHIBITORS AND GASTRIN COMPOUNDS | Waratah Pharmaceuticals, Inc. (CA) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008071010-A1 | COMBINATION TREATMENTS WITH SELECTED GROWTH/HORMONE REGULATORY FACTORS FOR DIABETES AND RELATED DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007095737-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES COMPRISING AN EXENDIN AGONIST AND A GASTRIN COMPOUND | WARATAH PHARMACEUTICALS INC. (CA) | 2007-08-30 | — | — | WO | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2007062531-A1 | COMBINATION TREATMENTS WITH GASTRIN AGONISTS FOR DIABETES AND RELATED DISEASES | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007041833-A1 | COMBINED USE OF DPP IV INHIBITORS AND GASTRIN COMPOUNDS | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-23 | — | — | US | disclosed |
| US-20030195237-A1 | Gastrin and cholecystokinin receptor lignads (iv) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-20030195240-A1 | Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-09 | — | — | US | disclosed |
| WO-2003041714-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
| WO-2001090078-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKIN IN RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001085704-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (IV) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085724-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085167-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PROTON PUMP INHIBITORS AND GASTRIN/CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-1993012817-A1 | THERAPEUTIC COMBINATIONS USEFUL IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE | WARNER-LAMBERT COMPANY (US) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195237-A1 | Gastrin and cholecystokinin receptor lignads (iv) | CCKAR, CCKBR, GRPR | GRIN2B 465/4885FABP7 1987/4885FABP5 1650/4885 |
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | CCKAR, CCKBR, GRPR | GRIN2B 942/4885FABP7 1058/4885FABP5 1781/4885 |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | GRIN2B 149/4885FABP7 190/4885FABP5 455/4885 |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | GRPR, CCKBR, GIPR | GRIN2B 619/4885FABP7 289/4885FABP5 481/4885 |
| US-20030195240-A1 | Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands | GIPR, CCKAR, CCKBR | GRIN2B 488/4885FABP7 2362/4885FABP5 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.